Understand the source comparison
Peptides for Insomnia Research: Clinical Application Comparison
| Peptide Class | Primary Mechanism | Sleep Target | Typical Research Dosage | Bottom Line ||—|—|—|—|| VIP (Vasoactive Intestinal Peptide) | VPAC2 receptor agonism in SCN; circadian entrainment | Delayed sleep phase, circadian rhythm disorders | 10–50 mcg subc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide Class | Primary Mechanism | Sleep Target | Typical Research Dosage | Bottom Line ||—|—|—|—|| VIP (Vasoactive Intestinal Peptide) | VPAC2 receptor agonism in SCN; circadian entrainment | Delayed sleep phase, circadian rhythm disorders | 10–50 mcg subcutaneous, timed to circadian phase | Targets upstream clock synchronization rather than acute sedation; requires weeks to shift circadian phase measurably || Pinealon | Pineal gland modulation; melatonin synthesis upregulation | Age-related sleep onset delay, reduced melatonin output | 1–3 mg oral or subcutaneous daily | Investigational for age-related circadian decline; most effective when administered 4–6 hours before desired sleep onset || Ipamorelin | Selective ghrelin receptor agonism; GH secretion and SWS enhancement | Reduced slow-wave sleep, poor sleep quality despite adequate duration | 200–300 mcg subcutaneous before bed | Increases SWS percentage without suppressing REM; most consistent effects seen in subjects over age